Anna Mc Laughlin, Dr. rer.nat.



  • Joined Pharmetheus in 2022, actively working in client projects
  • Expertise includes model-informed drug development, model-informed precision dosing, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, and virology
  • Previously worked as Senior Scientist at Freie Universitaet Berlin, Germany, where she performed pharmacometric research in therapeutic areas such as oncology and immuno-oncology
  • Pharmacist (2017) and Dr.rer.nat. in Pharmacometrics (2021) from Freie Universitaet Berlin, Germany
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modelingModel-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingPotential strategies to optimize CAR-T cell exposure in absence of dose-exposure relationships leveraging cell kinetic/dynamic models